Association of Neuroimaging Markers of Cerebral Small Vessel Disease With Short-Term Outcomes in Patients With Minor Cerebrovascular Events

Xuemei Chen (✉ 13347808579@189.cn)  
The Affiliated Jiangning Hospital with Nanjing Medical University

Lin Wang  
The Affiliated Jiangning Hospital with Nanjing Medical University

Junying Jiang  
The Affiliated Jiangning Hospital with Nanjing Medical University

Yuanyuan Gao  
The Affiliated Jiangning Hospital with Nanjing Medical University

Rui Zhang  
The Affiliated Jiangning Hospital with Nanjing Medical University

Xiaoyuan Zhao  
The Affiliated Jiangning Hospital with Nanjing Medical University

Tingwen Shen  
The Affiliated Jiangning Hospital with Nanjing Medical University

Qi Dai  
The Affiliated Jiangning Hospital with Nanjing Medical University

Junrong Li  
The Affiliated Jiangning Hospital with Nanjing Medical University

Research article

Keywords: white matter hyperintensity, cerebral small vessel disease, burden, minor cerebrovascular events, outcome

DOI: https://doi.org/10.21203/rs.3.rs-57506/v4

License: Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Increasing evidences have showed that neuroimaging markers of SVD can predict the short-term outcome of acute ischemic stroke (AIS). It is unclear that whether neuroimaging markers of SVD are also associated with short-term outcomes of minor cerebrovascular events. In the present study, we investigate neuroimaging markers of SVD in order to explore their roles in prediction of short-term outcome in patients with minor cerebrovascular events.

**Methods:** Consecutive first-ever stroke patients (n=546) from the Affiliated Jiangning Hospital of Nanjing Medical University were enrolled. A total of 388 patients were enrolled according to minor cerebrovascular events definition: National Institutes of Health Stroke Scale Score ≤ 3 and exclusion criteria. MRI scans were performed within seven days of stroke onset, and then neuroimaging markers of SVD including WMH, lacunes, cerebral microbleeds (CMB), and perivascular spaces (PVS), SVD burden scores were assessed. We completed baseline characteristics and evaluated the relationships of short-term outcomes to SVD neuroimaging markers and SVD scores. The 90-day modified Rankin Scale (mRS) was thought as primary outcome and was dichotomized as good functional outcome (mRS 0-1) and poor outcome (mRS 2-6). Secondary outcomes were stroke progression and stroke recurrence.

**Results:** Higher age, National Institutes of Health Stroke Scale (NIHSS) upon admission, lipoprotein-associated phospholipase A2 (LP-PLA2) and lacunes, Fazekas score were correlated with poor functional outcome (P<0.05). But after adjusting for confounding variables, among the neuroimaging markers of cerebral small vessel disease, only Fazekas score (OR, 1.343; 95% confidence interval, 1.020-1.770; P=0.036) was found to be associated with poor outcome at 90 days. Higher Fazekas and SVD scores were not associated with stroke progression or stroke recurrence.

**Conclusion:** WMH can predict the poor functional outcome of minor cerebrovascular events. Adding other neuroimaging markers of SVD and total SVD burden score, however, does not improve the prediction, which indicated WMH can as neuroimaging markers for guiding the treatment of minor cerebrovascular events.

**Background**

Cerebral small vascular disease (SVD) is an imaging, pathological and clinical syndrome caused by intracranial small vessel disease [1]. WMH, presented as high signal lesions on fluid-attenuated inversion recovery (FLAIR) sequence, is a common disease in the elderly [2] and has been proposed as a radiographic marker of SVD. Epidemiological studies revealed that about 70% of people over 65 years present with different degrees of WMH after undergoing magnetic resonance imaging (MRI) [3, 4]. The clinical significance of WMH is based on its robust associations with an increased risk of first or recurrent ischemic stroke [5, 6], intracerebral hemorrhage [7, 8], dementia [9, 10], and mortality [11].
However, WMH is just thought to be one of the MRI markers of SVD. Other standard definitions of SVD markers include lacunes, lobar and deep cerebral microbleeds (CMB), and enlarged perivascular spaces (PVS)\[^{12}\]. WMH and SVD burden may signify a diminished capacity of cerebral tissue to withstand ischemia. Various neuroimaging markers of SVD could be poor prognostic markers for ischemic stroke survivors. However, to date only a few studies have combined these SVD features to capture total SVD burden and explore the association of them with the risk and severity of stroke, such as the SVD burden independently predicts higher acute ischemic stroke (AIS) risk\[^{13}\] and more serious stroke\[^{14, 15}\]. Minor cerebrovascular events\[^{16}\]National Institutes of Health Stroke Scale Score\(\leq 3\) as an important part of AIS tend to recur and progress. And few studies have investigated the association of the SVD burden with short-term outcome in patients with minor cerebrovascular events.

We, therefore, aimed to undertake the present study to determine whether WMH or total SVD burden could be useful as a MRI marker for short-term outcome of minor cerebrovascular events.

**Methods**

**Study population**

In the prospective study, we analyzed data of minor cerebrovascular events patients, aged 45 to 85 years, enrolled from March 1, 2018 to March 1, 2020 from the department of neurology, Affiliated Jiangning Hospital of Nanjing Medical University. AIS patients were defined based on their clinical presentation and/or the presence of hyperintense lesion on Diffusion Weighted Imaging (DWI). For stroke patients with no DWI lesion, stroke diagnosis was confirmed by two experienced stroke clinician based on the clinical manifestations. The patients with severe head injury, multiple sclerosis, severe cerebral infarction, cerebral hemorrhage, rheumatic diseases or brain malignancy were excluded.

Finally, a total of 388 consecutive eligible patients were enrolled according to the minor cerebrovascular events definition\(\text{National Institutes of Health Stroke Scale Score} \leq 3\) and exclusion criteria\[^{16}\]. All the patients were first-ever minor ischemic stroke. The exclusion criteria were as followed: (1) Premorbid modified Rankin Scale (mRS) score of \(\geq 2\) (n=11); (2) Thrombolysis therapy for patients with strokes within 4.5 hours of symptom onset(n=51); (3) No baseline MRI (n=17) or one or more of the sequences essential for the calculation of SVD score were missing (n=9); (3) Lacking complete clinical data (n=21); (4) Patients without follow-up data at 3 months missing (n=25); (5) Refused to join in the study (n=16); (6)Deaths from other causes (n=8), with a total of 388 patients left (Figure 1).

The present study was approved by the ethics committee of Jiangning Hospital Affiliated to Nanjing Medical University. Written informed consent was obtained from all participants.

**Risk factors**
Patients underwent a neurological examination after admission. For determination of the subtype of ischemic stroke, the original TOAST (Trial of ORG 10172 in Acute Stroke Treatment) criteria were used. These 5 major categories of the TOAST classification are as follows: large-artery atherosclerosis (LAA), including large-artery thrombosis and artery-to-artery embolism; cardioembolism (CE); small-artery occlusion (SAO); stroke of other determined cause (OC); and stroke of undetermined cause (UND).

After admission, we collected data of patients’ demographic characteristics and traditional vascular risk factors\(^8\), including age and sex, history of hypertension, history of diabetes mellitus, history of dyslipidemia, history of atrial fibrillation, history of coronary heart disease; history of thrombolysis, history of embolectomy, cigarette or alcohol use. we also collected laboratory results, including results for fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglycerides (TG), low density lipoprotein cholesterol (LDL-C), homocysteine (Hcy), lipoprotein-associated phospholipase A2 (Lp-PLA2), high C-reactive protein (H-CRP), and D-Dime.

**Color Doppler ultrasonography (CDU) of the carotid artery**

For each patient, we also measured the intima plaques and intima–media thickness (IMT) using a Philips S3000 ultrasound machine (Philips HD20, Netherlands). We observed the formation of intima plaques and measured the IMT using a 7.5- to 10-MHz probe frequency. Plaque formation was diagnosed when the local IMT was > 1.2 mm or > 1.5 times the surrounding IMT\(^{17}\). Stable plaques were hard and flat, while unstable plaques were soft, ulcerative, and mixed. The site selected for IMT quantitative measurement was 1.5cm distal to the carotid artery bifurcation\(^{17}\). Two sonographers participated in the evaluation of CDU results.

**Radiologic data**

**MRI acquisition**

MRI scanning was performed within seven days of stroke onset on a 3.0 T MRI scanner (Ingenia, Philips Medical Systems, the Netherlands) with an 8-channel receiver array head coil. High-resolution T1-weighted axial images covering the whole brain were obtained by a 3D-magnetization prepared rapid gradient-echo sequence: TR = 8.1 ms; FA = 90°; TE = 3.7ms; FOV =240×240mm; acquisition matrix = 240×222; gap = 0 mm, thickness = 1.0 mm; number of slices = 170. T2-weighted; TR = 4000 ms; TE =107ms; FA = 90°; FOV =230×230mm acquisition matrix = 384×384; thickness = 1.5 mm; gap = 0 mm, number of slices = 18. DWI-weighted TR = 2503 ms; TE =98ms; FA =90°; FOV =230×230mm acquisition matrix =152×122; thickness = 1.5 mm; gap = 0 mm, number of slices = 18. Susceptibility weighted imaging (SWI)-weighted TR = 16 ms; TE =23ms; FA =10°; FOV =220 ×180 mm; acquisition matrix = 220×180; thickness = -.6 mm; gap = 0 mm, number of slices = 200. Additionally, the T2 fluid-attenuated inversion recovery (FLAIR) axial images were obtained with the following parameters: TR = 10000 ms; TE = 120 ms; FA =110°; FOV =220× 220mm; acquisition matrix = 336×189; thickness = 1.5 mm; gap = 0 mm, number of slices =18.
Fazekas score and SVD burden score

Results are reported in accordance with STRIVE\cite{12}. Fazekas score was used to score WMH\cite{18}. We used the previously described total SVD burden score\cite{13,14}, an ordinal scale (0 to 4) counting the presence of each of the four MRI markers for SVD. In more details, SVD burden score was composed of: (1) WMH was graded using the Fazekas score on FLAIR and divided into periventricular and deep WMH according to the lesion location. If confluent WMH (Fazekas score 2 and 3) were present, one point was awarded (Figure 2A). (2) lacunar infarcts: presence of one or more lacunes was defined as sharply demarcated hypointense lesions sized between<15 mm in diameter on T1-weighted images with corresponding hypointense lesions with hyperintense rim on FLAIR\cite{13,14}. (Figure 2B). (3) CMB were defined as round hypointense lesions on SWI-weighted gradient echo-images with a diameter <10mm. CMB were then divided to lobar versus deep\cite{18}. If \( \geq 1 \) deep or lobar CMB were present one point was awarded (Figure 2C). (4)PVS were defined as smooth margin, round, oval, or linear-shaped lesions, \( \leq 3 \) mm, with signal intensity equal to cerebrospinal fluid (CSF) on T1-weighted images\cite{19,20}. We counted PVS in the most affected hemisphere. One point was awarded if 30 or more PVS were present at any of the locations (Figure 2D). Two experienced neurologists and a neuroradiologist participated in the evaluation of MRI results.

Patient Outcomes

We rated the 90-day modified Rankin Scale (mRS) outcome and dichotomized as good functional outcome (mRS 0-1) and poor functional outcome (mRS 2-6) at 90 days\cite{21}. Stroke progression was defined as a worsening deficit during hospitalization compare with NIHSS score at the baseline assessment\cite{22}. A recurrent stroke was defined as a new sudden focal neurological deficit (vascular, >24 hours), which occurs at any time between the initial attack and 90-day follow-up mandating repeat imaging\cite{22}. These outcome events were reviewed in detail by 2 experienced neurologists and a neuroradiologist, and a consensus decision was made on progression or recurrence of stroke\cite{21,22}.

Statistical Analysis

Statistical analysis was conducted using SPSS software (Version 17.0, SPSS Inc., USA). Mean (standard deviation) or median (interquartile range) measurements were used to describe continuous variables which had a normal or non-normal distribution. Frequencies were used to describe categorical variables. Normality was confirmed by the Kolmogorov-Smirnov test. Inter-group comparisons for a normally distributed data were performed using the independent sample t test. The \( \chi^2 \) tests, Mann-Whitney and the Kruskal–Wallis tests were used to assess categorical variables and non-normally distributed continuous variables. Multiple linear regression analysis was used to explore association of SVD burden and WMH with poor outcome, progression, and recurrence at 90 days controlling for age, gender, vascular risks and admission NIHSS. Furthermore, univariate and multivariate logistic regression analysis was used to ascertain the
likelihood that patients will develop poor-outcome after 90 days. Variables with a $P<0.05$ in univariate regression analyses and other risk factors related to prognosis of minor cerebrovascular events were included in the multivariate logistic-regression models. $P<0.05$ was considered statistical significance.

**Results**

**Baseline Characteristics According to Classification of mRS Score**

Totally, 388 patients were included in the final analysis with 317 (81.70%) patients had good outcome and 71 (18.30%) patients had poor outcome. Mean age upon admission was 66.54 ± 11.15 years, and 61% were female. In the SVD burden score, 289 (74.48%) cases had WMH, 57 (14.69%) cases had CMB, 321 (82.73%) cases had lacunes, and 264 (68.04%) cases had PVS. With significant differences in age, admission NIHSS, LP-PLA2, lacunes, Fazekas score (either periventricular WMH score or deep WMH score) and Fazekas score after 3 months (either periventricular WMH score or deep WMH score) between the good outcome and poor outcome ($P<0.05$). No significant differences were found in other baseline characteristics (The details were showed in Table 1).

**Univariate and Multivariate Logistic Regression Analysis of Poor functional outcome**

After 90 days of the minor cerebrovascular events, we observed 71 (18.30%) patients had poor outcome. In univariable logistic regression analysis, age (OR, 1.054; 95% confidence interval, 1.026-1.082; $P<0.01$), LP-PLA2 (OR, 1.005; 95% confidence interval, 1.003-1.008; $P<0.01$), Fazekas score (OR, 1.501; 95% confidence interval, 1.241-1.816; $P<0.01$), lacunes (OR, 1.501; 95% confidence interval, 1.016-3.856; $P=0.045$) and NIHSS upon admission (OR, 1.980; 95% confidence interval, 1.223-1.464; $P<0.01$) were associated with poor outcome at 90 days. In the multivariable logistic regression analysis, after adjusting for other confounding variables, age (OR, 1.053; 95% confidence interval, 1.009-1.099; $P=0.019$), LP-PLA2 (OR, 1.006; 95% confidence interval, 1.003-1.009; $P<0.01$), Fazekas score (OR, 1.343; 95% confidence interval, 1.020-1.770; $P=0.036$), and NIHSS upon admission (OR, 1.322; 95% confidence interval, 1.163-1.502; $P<0.01$) were associated with poor outcome at 90 days (Table 2).

**Association of SVD Burden and WMH with Poor functional outcome, Progression, and Recurrence at 90 Days**

Univariate logistic regression analysis showed higher Fazekas scale score at baseline was associated with poor functional outcome at 90 days (defined as mRS score 2-6) (OR, 1.501; 95% confidence interval, 1.241-1.816; $P<0.01$), but they were not associated with stroke progression, stroke recurrence ($P>0.05$). Similarly, higher SVD burden score also was not associated with poor outcome at 90 days, stroke progression and stroke recurrence ($P>0.05$) (Table 3).

**Discussion**
In the present study, we recruited first-ever minor cerebrovascular events patients and follow-up of 90 days. We found there were 71 (18.30%) patients had poor outcome after 90 days. In the MRI makers of SVD, just WMH score at baseline was associated with poor functional outcome at 90 days. In the prediction model, we found WMH score and admission NIHSS can as the independent predictor of poor functional outcome at 3 months after stroke onset.

Increasing evidences have showed that the WMH burden is a negative prognostic marker after AIS\textsuperscript{[6, 10, 23]}. Recently, a large study on more than 5000 first-ever ischemic stroke patients showed that higher supratentorial-WMH volumes were associated with higher 3-month mRS scores\textsuperscript{[24]}. Additionally, brainstem-WMH is proved to be an independent predictor of poor outcome after AIS/TIA and this relationship persist after adjustment for important prognostic factors\textsuperscript{[24]}. Importantly, in our analyses, WMH remained independently associated with less functional recovery after controlling for age and other confounding factors, which suggested it is important to understand the pathological mechanism of the influence of WMH on the prognosis of ischemic stroke, but it remains poorly understood so far\textsuperscript{[25]}. It has been hypothesized that WMH could weaken brain plasticity and capacity to compensate for ischemic injury, partly due to a disruption of white matter fiber tract organization and neuronal network integrity\textsuperscript{[26]}. A possible explanation for this could be that patients with severe WMH have hemodynamic impairment of the distal arteries/terminal arterioles and that this produces a tendency for poor ischemic tissue outcomes. Our finding indicates that the burden of WMH may represent a certain degree of brain fragility, and its addition to chronological age determines an individual's capacity of post-stroke recovery more accurately than chronological age itself. Our study, therefore, could add to the growing body of literatures suggesting that the extent of WMH affects recovery in patients with stroke. Efficient post-stroke recovery entails reorganization of brain networks, which might be compromised in brains with advanced WMH. In addition, the severity of WMH is associated with post-stroke cognitive decline and depression, and these secondary phenomena are likely to synergistically contribute to unfavorable recovery\textsuperscript{[27]}. In recent years, relationship between SVD burden and clinical outcome of stroke patients has drawn attracted much attention. Some studies have shown that the SVD burden is superior to that of any single SVD marker, although no relationship was found in our study. The lack of association between other SVD markers and poor post-stroke outcome may imply that these SVD markers are not detected on conventional imaging or because of a small sample. With the development of imaging technology, other potential SVD markers may be found one by one, such as cerebral microinfarction, which could more comprehensively evaluate the prognosis of stroke patients\textsuperscript{[16, 28, 29]}. In addition, the poor outcome group had a significantly higher NIHSS scores than the good outcome group. NIHSS is a 15-item neurological function scale used in patients with minor cerebrovascular events. The WMH score increased with the severity of neurological impairment and high scores indicate a worse prognosis for minor cerebrovascular events patients.
The design and patient population of this study offer several strengths including the prospective, single center, first-ever stroke cohort, the identical 3T MRI protocol and the comprehensive outcome assessment used for all patients. In addition, MRI features of SVD were rated according to the standard neuroimaging characteristics of SVD.

Several limitations should be considered. Firstly, the prospective observational study has a possible selection bias, given that patients with severe AIS, contraindications for MRI, and fatal short-term outcome were missed. At the same time, we only chose patients aged 45 to 85 years. Secondly, the relatively small sample size could contribute to the lack of statistical power to detect smaller influences from other clinical or radiographic variables. Thirdly, SVD features were analyzed as classified but not continuous variables and the burden of WMH is just evaluated by Fazekas scores on FLAIR. Quantifying WMH burden may be more accurately predict the prognosis of minor cerebrovascular events and should be applied in the future work. Furthermore, the association of neuroimaging markers of CSVD with long-term outcomes in patients with minor cerebrovascular events has not been confirmed and it requires further specific longitudinal studies on large populations. Anyway, we are continuing to recruit new minor cerebrovascular events patients and follow-up them in different time points to validate our findings.

**Conclusion**

In summary, it was found that the WMH was correlated with short-term functional outcome of minor cerebrovascular events patients and can as a neuroimaging maker of predicting poor functional outcome after minor cerebrovascular events, which highlights the crucial influence of white matter structural integrity on stroke outcome. Taking early detection and treatment of WMH into consideration may be beneficial for improving the functional outcome of patients after minor cerebrovascular events.

**Declarations**

**Acknowledgements**

Not applicable.

**Authors' Contributions**

XMC, JRL, and YYG contributed to the study design. Data collection was performed by LW, JYJ and RZ. XYZ, QD, and TWS were responsible for data analysis. The manuscript was written by XMC and LW. All authors approved the final manuscript for publication.

**Funding**

This research was supported by Nanjing Medical Science and technique Development Foundation; Nanjing Medical University Science and Technology Development Project, Jiangsu, China; and Kangda College of Nanjing Medical University Science and Research Development Project, Jiangsu, China.
Availability of data and materials

Study data are available from the corresponding author upon request.

Ethics approval and consent to participate

We obtained ethical approval for this study from the ethics committee in the Affiliated Jiangning Hospital with Nanjing Medical University. Written informed consent was obtained from all study participants.

Consent for publication

Not applicable.

Competing interests

None.

Abbreviations

AIS, acute ischemic stroke; CSF, cerebrospinal fluid; CE, cardioembolism; CRP, c-reactive protein; CMB, lobar and deep cerebral microbleeds; DWI, diffusion weighted Imaging; FBG, glucose fasting blood glucose; FLAIR, fluid-attenuated inversion recovery; HbA1c, glycosylated hemoglobin; Hcy, homocysteine; IMT, intima–media thickness; LAA, large-artery atherosclerosis; LDL, low-density lipoprotein; Lp-PLA2, phospholipase A2; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NIHSS, national institutes of health stroke scale; OC, stroke of other determined cause; PVS, enlarged perivascular spaces; SAO, small-artery occlusion; SVD, small vascular diseases; SWI, susceptibility weighted imaging; TIA, transient ischemic attack; TC, total cholesterol; TG, triglycerides; UND, stroke of undetermined cause; WMH, white matter hyperintensity.

References

[1] Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol, 2013;12(5):483-497.

[2] Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London, England). 2017;390(10100):1084-1150.

[3] Schmidt R, Seiler S, Loitfelder M. Longitudinal change of small-vessel disease-related brain abnormalities. J Cereb Blood Flow Metab. 2016;36(1):26-39.

[4] Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701.
[5] Wong T, Klein R, Sharrett A, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA. 2002;288(1):67-74.

[6] Bokura H, Kobayashi S, Yamaguchi S, et al. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. J Stroke Cerebrovasc Dis. 2006;15(2):57-63.

[7] Chen X, Jin Y, Chen J, et al. Relationship between White Matter Hyperintensities and Hematoma Volume in Patients with Intracerebral Hematoma. Aging Dis. 2018;9(6):999-1009.

[8] Chen X, Chen X, Chen Y, et al. The Impact of Intracerebral Hemorrhage on the Progression of White Matter Hyperintensity. Front Hum Neurosci. 2018;12:471.

[9] Buyck J, Dufouil C, Mazoyer B, et al. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. Stroke. 2009;40(7):2327-2331.

[10] Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41(4):600-606.

[11] Folsom A, Yatsuya H, Mosley T, et al. Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol. 2012;71(4):552-559.

[12] Wardlaw J, Smith E, Biessels G, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838.

[13] Huijts M, Duits A, van Oostenbrugge R, et al. Accumulation of MRI Markers of Cerebral Small Vessel Disease is Associated with Decreased Cognitive Function. A Study in First-Ever Lacunar Stroke and Hypertensive Patient. Front Aging Neurosci. 2013;5:72.

[14] Staals J, Makin S, Doubal F, et al. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83(14):1228-1234.

[15] Klarenbeek P, van Oostenbrugge R, Rouhl R, et al. Ambulatory blood pressure in patients with lacunar stroke: association with total MRI burden of cerebral small vessel disease. Stroke. 2013;44(11):2995-2999.

[16] Molad J, Kliper E, Korczyn A, et al. Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study. J Alzheimers Dis. 2017;56(4):1293-1299.

[17] Huang L, Yao S. Carotid artery color Doppler ultrasonography and plasma levels of lipoprotein-associated phospholipase A2 and cystatin C in arteriosclerotic cerebral infarction. J Int Med Res. 2019;47(9):4389-4396.
[18] Fazekas F, Chawluk J, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-356.

[19] Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43(9):1683-1689.

[20] Greenberg S, Vernooij M, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8(2):165-174.

[21] Zerna C, Yu A, Modi J, et al. Association of White Matter Hyperintensities With Short-Term Outcomes in Patients With Minor Cerebrovascular Events. Stroke. 2018;49(4):919-923.

[22] Coutts S, Modi J, Patel S, et al. CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke. 2012;43(4):1013-1017.

[23] Henninger N, Lin E, Haussen D, et al. Leukoaraiosis and sex predict the hyperacute ischemic core volume. Stroke. 2013;44(1):61-67.

[24] Giralt-Steinhauer E, Medrano S, Soriano-Tárraga C, et al. Brainstem leukoaraiosis independently predicts poor outcome after ischemic stroke. Eur J Neurol. 2018;25(8):1086-1092.

[25] Etherton M, Wu O, Rost N. Recent Advances in Leukoaraiosis: White Matter Structural Integrity and Functional Outcomes after Acute Ischemic Stroke. Curr Cardiol Rep. 2016;18(12):123.

[26] Grefkes C, Fink G. Connectivity-based approaches in stroke and recovery of function. Lancet Neurol. 2014;13(2):206-216.

[27] Kliper E, Ben Assayag E, Tarrasch R, et al. Cognitive state following stroke: the predominant role of preexisting white matter lesions. PloS ONE. 2014;9(8):e105461.

[28] Auriel E, Westover M, Bianchi M, et al. Estimating Total Cerebral Microinfarct Burden From Diffusion-Weighted Imaging. Stroke. 2015;46(8):2129-2135.

[29] Nitkunan A, Lanfranconi S, Charlton R, et al. Brain atrophy and cerebral small vessel disease: a prospective follow-up study. Stroke. 2011;42(1):133-138.

Tables

Table 1. Baseline characteristics classified according to (mRS 0-1;2-6)
| Variables | Good outcome (mRS Score 0-1) at 90 d, n=317 | Poor outcome (mRS Score 2-6) at 90 d, n=71 | P Value |
|-----------|----------------------------------------|----------------------------------------|---------|
| Age, y, mean±SD | 65.50±11.14 | 71.23±9.98 | <0.01* |
| Women, n(%) | 198 (62%) | 39 (55%) | 0.239 |
| Admission NIHSS, median(IQR) | 1.25 (1-2.25) | 2.25 (2-3) | <0.01* |
| Hypertension | 262 (83%) | 62 (87%) | 0.337 |
| Coronary artery disease | 38 (12%) | 14 (20%) | 0.084 |
| Atrial fibrillation | 114 (36%) | 28 (39%) | 0.583 |
| Diabetes mellitus | 127 (40%) | 35 (30%) | 0.449 |
| Stroke | 49 (15%) | 12 (17%) | 0.621 |
| Hematencephalon | 38 (12%) | 13 (18%) | 0.712 |
| Smoking, n(%) | 262 (83%) | 62 (87%) | 0.006* |
| Alcohol, n(%) | 114 (36%) | 28 (39%) | 0.583 |
| Carotid atherosclerosis, percentage | 221 (76%) | 38 (78%) | 0.038 |
| OAST classification, percentage | 0.349 |
| Large artery | 69 (55%) | 19 (70%) |
| Small vessel disease | 44 (35%) | 8 (30%) |
| Cardioembolic | 10 (8%) | 0 (0%) |
| Undetermined | 3 (2%) | 0 (0%) |
| Clinical variables, median(IQR) | | | |
| HbAIc, % | 5.42 (4.86-6.75) | 5.63 (4.88-6.65) | 0.493 |
| FBG, mmol/L | 6.00 (5.50-7.30) | 5.90 (5.60-9.00) | 0.203 |
| TC, mmol/L | 4.16 (3.59-4.67) | 5.42 (2.94-4.81) | 0.255 |
| TG, mmol/L | 1.31 (0.96-1.86) | 1.29 (0.93-1.51) | 0.456 |
| LDL-C, mmol/L | 1.70 (0.80-6.93) | 3.10 (0.70-18.30) | 0.220 |
| H-CRP, mg/L | 143.00 (97.00-261.50) | 284.00 (208.00-391.00) | <0.01* |
| Hcy,umol/L | 12.50 (9.90-15.50) | 11.30 (10.10-14.60) | 0.328 |
| D-Dimer,mg/L | 0.34 (0.25-0.53) | 0.27 (0.38-0.69) | 0.414 |
| D-Dimer,mg/L | 0.34 (0.25-0.53) | 0.27 (0.38-0.69) | 0.414 |
| VD burden score, median(IQR) | 3 (2-3) | 3 (1-3) | 0.894 |
| SVD score is 0, n(%) | 4 (1%) | 2 (3%) |
| SVD score is 1, n(%) | 60 (19%) | 16 (23%) |
| SVD score is 2, n(%) | 94 (30%) | 15 (21%) |
| SVD score is 3, n(%) | 132 (42%) | 30 (42%) |
| SVD score is 4, n(%) | 27 (9%) | 8 (11%) |
| WMH, n(%) | 227 (18%) | 62 (87%) | 0.038 |
| Periventricular WMH core | 2 (1-3) | 3 (2-3) | <0.01* |
| Deep WMH score | 3 (1-3) | 3 (2-3) | 0.020* |
| VD burden score after 3 months, median(IQR) | 3 (2-3) | 3 (2-3) | 0.667 |
| SVD score is 0, n(%) | 4 (1%) | 2 (3%) | 0.006* |
| hypotesis score | 226 (71%) | 59 (83%) | 0.042* |
| VS, n(%) | 219 (69%) | 45 (63%) | 0.351 |
| MB, n(%) | 46 (15%) | 11 (16%) | 0.833 |
| Periventricular WMH core | 2 (1-3) | 3 (2-3) | <0.01* |
| Deep WMH score | 3 (1-3) | 3 (2-3) | 0.020* |
| VD burden score after 3 months, median(IQR) | 3 (2-3) | 3 (2-3) | 0.667 |
| SVD score is 0, n(%) | 4 (1%) | 2 (3%) | 0.006* |
| SVD score is 1, n(%) | 57 ( 18% ) | 13 (18% ) |
| SVD score is 2, n(%) | 96 ( 30% ) | 18 (25% ) |
| SVD score is 3, n(%) | 133 ( 42% ) | 29 (41% ) |
| SVD score is 4, n(%) | 27 ( 9% ) | 9 (13% ) |

| azekas score after 3 months, median(IQR) | 4 ( 2.5-6 ) | 5 (4-6 ) |

| Periventricular WMH core | 2 ( 1-3 ) | 3 ( 2-3 ) |
| Deep WMH score | 3 ( 1-3 ) | 3 ( 2-3 ) |

Note: *significant difference (P < 0.05); FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; H-CRP, high C-reactive protein; Hcy, homocysteine; LP-PLA2, lipoprotein-associated phospholipase A2; SVD, cerebral small vascular diseases; WMH, white matter hyperintensity; PVS, enlarged perivascular spaces; CMB, cerebral microbleeds.

### Table 2. Univariate and multivariate logistic regression analysis of poor outcome at 90 Days

| Variables     | Univariate OR ( 95%CI ) | P value | Multivariate OR ( 95%CI ) # | P value |
|---------------|------------------------|---------|----------------------------|---------|
| Mission NIHSS | 1.054 (1.026-1.082 )   | <0.01*  | 1.053 (1.009-1.099)         | 0.019*  |
| PLA2          | 1.338 (1.223-1.464)    | <0.01*  | 1.322 (1.163-1.502)         | <0.01*  |
| Ekas score    | 1.005 (1.003-1.008)    | <0.01*  | 1.006 (1.003-1.009)         | <0.01*  |
| Unes          | 1.501 (1.241-1.816)    | <0.01*  | 1.343 (1.020-1.770)         | 0.036*  |
| Unes          | 1.980 (1.016-3.856)    | 0.045*  | 2.317 (0.818-6.561)         | 0.133   |

Note: *significant difference (P < 0.05); LP-PLA2, lipoprotein-associated phospholipase A2.
#Odds ratios were adjusted for baseline characteristics of patients.

### Table 3. Association of SVD burden score and WMH With poor outcome, Progression, and Recurrence at 90 Days
| Variables                              | OR (95%CI)                          | P Value |
|---------------------------------------|-------------------------------------|---------|
| Poor outcome: mRS: 2-6: 71/388 = 17.64% |                                     |         |
| SVD burden score                      | 0.993 (0.757-1.303)                 | 0.961   |
| Fazekas score                         | 1.501 (1.241-1.816)                 | <0.01*  |
| Periventricular WMH score             | 1.825 (1.365-2.441)                 | <0.01*  |
| Deep WMH score                        | 1.477 (1.095-1.992)                 | 0.011*  |
| Recurrent stroke: 11/388 = 2.84%     |                                     |         |
| SVD burden score                      | 0.809 (0.434-1.505)                 | 0.503   |
| Fazekas score                         | 1.012 (0.715-1.432)                 | 0.946   |
| Periventricular WMH score             | 0.673 (0.384-1.179)                 | 0.166   |
| Deep WMH score                        | 2.055 (0.810-5.214)                 | 0.130   |
| Progression stroke: 5/388 = 1.29%    |                                     |         |
| SVD burden score                      | 0.532 (0.211-1.346)                 | 0.183   |
| Fazekas score                         | 1.441 (0.740-2.806)                 | 0.283   |
| Periventricular WMH score             | 4.102 (0.713-23.581)                | 0.114   |
| Deep WMH score                        | 0.969 (0.410-2.294)                 | 0.944   |

Note: *significant difference ($P < 0.05$);

SVD, cerebral small vascular diseases; WMH, white matter hyperintensity.

**Figures**

![Diagrammatic sketch of the screening process.](image_url)
Figure 2

MRI manifestations of cerebral small vessel disease. (A) WMH, high signal lesions on fluid-attenuated inversion recovery sequence; (B) Lacunes, small cerebrospinal fluid-containing cavities larger than 3mm and smaller than 15mm in diameter on T1-weighted; (C) CMB, small punctuate areas of hypointensity on susceptibility-weighted imaging measuring up to 10mm in diameter; (D) PVS, the small deep perforating arterioles as they pass through the deep grey and white matter, made visible on T2-weighted by containing increased fluid of similar signal to CSF.